Aspen has businesses in South Africa, Australia, India, Brazil, Mexico, Venezuela, Kenya, Tanzania, Uganda, Mauritius and the United Kingdom and exports to many other territories across the globe.

Aspen, listed on JSE Ltd, is Africa’s largest pharmaceutical manufacturer, a major supplier of branded and generic pharmaceutical, healthcare and nutritional products to the southern African and selected international markets.

Aspen is the largest generics manufacturer in the southern hemisphere and is also the leading supplier of generic medicines to both the private and the public sectors in South Africa.

Aspen is one of the top twenty generic manufacturers worldwide and South Africa’s number one generic brand.

Aspen has fifteen pharmaceutical manufacturing facilities on eleven pharmaceutical manufacturing sites on three continents. Four of the sites are located in South Africa, two in India, two in East Africa and three in Latin America.

Aspen has production capabilities for a wide variety of product types including tablets, capsules, steriles, injectables, penicillins, penems, infant milk formulations, liquids and creams.

Aspen is one of the leading global players in generic antiretrovirals (“ARVs”).

Aspen has an outstanding generic pipeline. These products are developed under the direction of highly skilled scientists employed by Aspen and in collaboration with other global pharmaceutical companies and research facilities.

Aspen products are renowned for their quality, efficacy and affordability. The Group’s extensive basket includes branded, generic, over-the-counter, self medication, personal care and infant nutritional products.

The four branded products recently acquired from GlaxoSmithKline Group Limited (“GSK”) for R2,7 billion will be distributed to more than 100 countries globally.